Please find enclosed press release

Pat Growth 25pctRevenue Growth 20pctEbitda Margin CompressionResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.6%Reaction day

₹44.20

prior close

₹42.80

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.0%-4.6% vs market

Pharmaceuticals peers, median of 164sector+0.1%-4.8% vs sector

On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-2.1

15m

-2.3

30m

-2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.6-0.0-4.6+0.1-4.8

Next day

-2.5-0.7-1.8-0.5-2.0

+4.8-1.8+6.5-1.3+6.1

+3.0-0.7+3.7-1.4+4.4

+2.5-0.5+2.9-1.6+4.1

+1.9+0.4+1.5-0.6+2.5

-3.6-1.6-2.0-2.3-1.4

15d

+15.6+4.6+11.0+0.0+15.6

+23.8+4.6+19.2+3.0+20.8

+28.1+6.1+21.9+4.3+23.8

+117.7+10.8+106.9+8.6+109.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Laboratories reported strong Q4 FY26 with net profit jumping 69% YoY to Rs. 20 crore and gross revenue rising 22% YoY to Rs. 472 crore. The company's Rs. 825 crore (USD 91 million) CDMO mandate from a global multinational has commenced commercial production with validation batches completed. API business grew 17% and Medical Devices surged 31% in Q4. For FY26, standalone revenue crossed Rs. 1,700 crore (up 8%) with Medical Devices revenue at Rs. 598 crore (up 21%). EBITDA stood at Rs. 32 crore vs Rs. 33 crore in Q4 FY25, reflecting near-term margin compression from growth investments. The company completed its 4th consecutive USFDA inspection with zero 483 observations and is expanding capacity from ~500 KL to ~800 KL.

Likely market impact

The 69% jump in net profit and commencement of the Rs. 825 crore CDMO program signal strong growth momentum. The proposed 10% dividend rewards shareholders. However, EBITDA margin compression due to investments may weigh on near-term profitability despite promising long-term growth from capacity expansion and regulated-market programs.